Immunotherapy represents a new hope for patients with advanced urothelial carcinoma (UC). However, to date, only one of two randomized studies showed a clear survival advantage with these treatments. Aimed to investigate the role of immune-checkpoint inhibitors in patients with platinum progressed metastatic UC we performed a systematic review and meta-analysis of clinical trials to evaluate the efficacy and activity, in terms of Overall Survival (OS) and Objective Response Rate (ORR). Immune checkpoint inhibitors have showed to improve OS compared to chemotherapy in unselected patients (HR 0.80, 95% CI 0.69–0.93, p = 0.003), while the difference was not significant in patients selected for PD-L1 expression (HR 0.72, 95% CI 0.48–1.09, p = 0.12). Pooled probability of response was 0.18 (95% CI 0.16–0.20) in unselected patients and 0.27 (95% CI 0.25–0.32) in PD-L1 selected patients. Immunotherapy results in a significant survival advantage in PD-L1 unselected patients suggesting that PD-L1 expression may not be a reliable marker in previously platinum treated patients.

Di Nunno, V., De Luca, E., Buttigliero, C., Tucci, M., Vignani, F., Gatto, L., et al. (2018). Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 129, 124-132 [10.1016/j.critrevonc.2018.07.004].

Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis

Di Nunno, Vincenzo;Gatto, Lidia;Ardizzoni, Andrea;Massari, Francesco
2018

Abstract

Immunotherapy represents a new hope for patients with advanced urothelial carcinoma (UC). However, to date, only one of two randomized studies showed a clear survival advantage with these treatments. Aimed to investigate the role of immune-checkpoint inhibitors in patients with platinum progressed metastatic UC we performed a systematic review and meta-analysis of clinical trials to evaluate the efficacy and activity, in terms of Overall Survival (OS) and Objective Response Rate (ORR). Immune checkpoint inhibitors have showed to improve OS compared to chemotherapy in unselected patients (HR 0.80, 95% CI 0.69–0.93, p = 0.003), while the difference was not significant in patients selected for PD-L1 expression (HR 0.72, 95% CI 0.48–1.09, p = 0.12). Pooled probability of response was 0.18 (95% CI 0.16–0.20) in unselected patients and 0.27 (95% CI 0.25–0.32) in PD-L1 selected patients. Immunotherapy results in a significant survival advantage in PD-L1 unselected patients suggesting that PD-L1 expression may not be a reliable marker in previously platinum treated patients.
2018
Di Nunno, V., De Luca, E., Buttigliero, C., Tucci, M., Vignani, F., Gatto, L., et al. (2018). Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 129, 124-132 [10.1016/j.critrevonc.2018.07.004].
Di Nunno, Vincenzo; De Luca, Emmanuele; Buttigliero, Consuelo; Tucci, Marcello; Vignani, Francesca; Gatto, Lidia; Zichi, Clizia; Ardizzoni, Andrea; Di...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/671520
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact